OBJECTIVE: To perform a systematic review and meta-analysis comparing doublet versus single agent therapy in elderly @entity1 with @entity1149 ( @entity1149 ). METHODS: PubMed   and Cochrane databases, and American Society of Clinical Oncology, World Congress of @entity2 , and European Society of Medical Oncology abstracts were searched. Endpoints were @entity1349 ( @entity1349 ), 1-year survival rate (1-year SR), overall response rate (ORR), and grade 3/4 adverse events. Subgroup analyses were based on chemotherapy regimens and race. RESULTS: Out of 11 studies (13 randomized trials; n   =   2782), doublet therapy was associated with significantly increased @entity1349 (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.83, 0.95), 1-year SR (risk ratio [RR] 1.15, 95% CI 1.04, 1.28), and ORR (RR 1.39, 95% CI 1.39, 1.86) versus single-agents. Chemotherapy regimen-based subgroup analyses favoured @entity902 -based doublet therapy for @entity1349 (RR 0.71, 95% CI 0.60, 0.84), 1-year SR (RR 1.28, 95% CI 1.11, 1.47), and ORR (RR 1.88, 95% CI 1.49, 2.38). Race-based subgroup analyses revealed increased benefit from doublet therapy in Asian populations for ORR (RR 1.70, 95% CI 1.29, 2.23) but not increased survival benefit. Higher incidences of grade 3/4 @entity417 (RR 2.23, 95% CI 1.61, 3.09), @entity882 (RR 2.47, 95% CI 1.17, 5.20), and fatigue (RR 1.36, 95% CI 1.06, 1.74) were observed with doublet versus single-agent therapy. CONCLUSIONS: Doublet therapy was associated with significantly increased @entity1349 , 1-year SR and ORR compared with single agent therapy. Race may be considered when choosing doublet versus single-agent therapy as first-line treatment of @entity1149 in elderly @entity1 .

Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'advanced nonsmall-cell lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung Cancer'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1149 :: (MESH:D002289,Disease) :: ['advanced nonsmall-cell lung cancer']
